Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

18.95EUR
11:35am EST
Change (% chg)

€-0.13 (-0.68%)
Prev Close
€19.08
Open
€19.01
Day's High
€19.60
Day's Low
€18.60
Volume
64,667
Avg. Vol
52,658
52-wk High
€29.78
52-wk Low
€18.60

Summary

Name Age Since Current Position

Andre Choulika

53 2000 Chairman of the Board, Chief Executive Officer, Member of the Executive Board

David Sourdive

2016 Deputy Chief Executive Officer, Executive Vice President Technical Operations, Member of the Executive Committee, Director

Eric Dutang

45 Chief Financial Officer, Member of the Executive Committee

Elsy Boglioli

2018 Chief Operating Officer, Executive Vice President - Strategy and Corporate Development, Member of the Executive Committee

Stephane Depil

2017 Senior Vice President - Research and Development and Chief Medical Officer , Member of the Executive Committee

Stephan Reynier

Chief Regulatory and Compliance Officer, Member of the Executive Committee

Marie-Bleuenn Terrier

2013 General Counsel, Member of the Executive Committee

Philippe Duchateau

2012 Chief Scientific Officer, Member of the Executive Committee

Laurent Arthaud

2011 Non-Executive Independent Director

Pierre Bastid

2011 Non-Executive Independent Director

Rainer Boehm

57 2017 Non-Executive Independent Director

Alain Godard

72 2007 Non-Executive Independent Director

Herve Hoppenot

58 2017 Non-Executive Independent Director

Jean-Marie Messier

2015 Non-Executive Independent Director

Annick Schwebig

2011 Non-Executive Independent Director

Biographies

Name Description

Andre Choulika

Dr. Andre Choulika is one of the founders of Cellectis SA and has been Chairman of the Board, Member of the Executive Committee and Chief Executive Officer since 2000. He has also been Chairman of Calyxt (previously Cellectis plant sciences) since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. He also served on the Boards of Directors of several biotechnology companies. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. Dr. Choulika also has management training from the HEC (Challenge +).

David Sourdive

Dr. David J.D. Sourdive has been Director, Executive Vice President Technical Operations, Member of Executive Committee and Deputy Chief Executive Officer at Cellectis SA since 2016. Previously he served as Company's Executive Vice President-Corporate Development and Director. From 2014, Dr. Sourdive also served on the Board of Directors of Mediterranean Institute for Life Sciences. He previously served on the Board of Directors of Medicen Paris Region and Seine Saint Denis Avenir. From 1998 to 2000, he directed the biotechnologies laboratory of the Centre d’Etudes du Bouchet for the French Ministry of Defense. Dr. Sourdive graduated from the Ecole Polytechnique and received his Ph.D. in molecular virology at the Institut Pasteur. He also has management training from the HEC (Challenge +). He is currently on the Board of Directors within MEDILS, Eukarys SAS and Omics SAS.

Eric Dutang

Mr. Eric Dutang serves as Chief Financial Officer and Member of the Executive Committee of Cellectis SA. Certified Public Accountant in France, joined Cellectis as Deputy Chief Financial Officer in May 2015. He began his career as financial auditor with KPMG, first in Paris for five years and then in New York for two years. He worked for publicly-traded companies in France and the U.S. including Vivendi, Veolia Environnement, and Cablevision. He then became a member of the transactions and advisory teams in Paris for seven years where he carried out acquisitions/disposals for both publicly-traded companies and private equity funds. After serving at KPMG, he worked on international business developments for French publicly-traded groups, including Air Liquide and Thales. Mr. Dutang holds a Master of Finance and Executive MBA from HEC Paris (France)/Babson Massachusetts (USA).

Elsy Boglioli

Ms. Elsy Boglioli is Chief Operating Officer, Executive Vice President - Strategy and Corporate Development of the Company as well as Member of Executive Committee. Ms. Boglioli's responsibilities include directing the long-term strategy and current business priorities of Cellectis to ensure that the overall mission of the Company is fulfilled. Ms. Boglioli joins Cellectis from Boston Consulting Group (BCG), where she served as Partner and Managing Director, and leader of BCG's biotech-focused business in Europe. Ms. Boglioli graduated from Ecole Polytechnique in Paris, France and holds a master's degree in economy and management from Pompeu Fabra University in Barcelona, Spain.

Stephane Depil

Prof. Stephane Depil, MD, PhD, is Senior Vice President - Research and Development and Chief Medical Officer of the Company, as well as Member of Executive Committee. Prof. Depil's responsibilities include bringing Cellectis' product candidates to clinical-stage development, strategic and operational management of all therapeutic activities, and supervising research and development projects for the Company. Prof. Depil is a board-certified physician in hematology, with over 15 years of experience in oncology clinical development, both in hospital / university and pharmaceutical companies. Prior to joining the Leon Berard Cancer Center & Cancer Research Center of Lyon, France as Medical Director of the Cancer Immunotherapy Program, he served as Chief Executive Officer at Netris Pharma, where he was responsible for the management of an oncology startup and preclinical development of a first-in-class monoclonal antibody in Phase I. Prior to Netris, he worked at Servier for 8 years in a variety of roles, including Director of Oncology Research and Development, where he managed 20 programs: 5 in the clinic, 7 at late preclinical stages, and 8 at early preclinical stages. He also directly supervised over 100 licensing opportunities.

Stephan Reynier

Mr. Stephan Reynier serves as Chief Regulatory and Compliance Officer and Member of the Executive Committee at Cellectis SA. He joined Cellectis in April 2011. r is in charge of ensuring a speedy and successful development of the UCART product family by establishing close interactions with regulatory agencies such as EMA and FDA, while securing compliance to applicable regulations, regulatory guidelines and quality assurance standards. Mr Reynier has extensive experience, from his previous positions as Senior Director at Voisin Consulting Life Sciences and European Associate Director Medical Affairs at Gilead Sciences, in the design and implementation of regulatory strategies for the development of drugs and biologics, with a strong focus on cell and gene therapy. Mr Reynier graduated as Agro-Engineer in France and received a Master of Science in Chemical Engineering from the University of Toronto, Canada.

Marie-Bleuenn Terrier

Ms. Marie-Bleuenn Terrier has been General Counsel and Member of the Executive Committee of Cellectis since 2013. Prior to joining Cellectis, she worked as Legal Counsel for Pfizer from 2004 to 2006, and for Boehringer Ingelheim from 2006 to 2008. She holds a Master’s degree in Law from Universite Paris 1 Pantheon-Sorbonne.

Philippe Duchateau

Dr. Philippe Duchateau has served as Chief Scientific Officer and Member of Executive Committee at Cellectis SA since January 30, 2012. He joined the Company in 2001 and he served as Head of Research Department from 2004. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur (Lille, France), he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco (United States) within the Cardiovascular Research Institute. He is co-inventor of numerous patents in the field of nucleases and gene editing and co-author on more than 50 scientific publications and co-editor of one book entitled Site-directed Insertion of Transgenes.

Laurent Arthaud

Mr. Laurent Arthaud has served as Non-Executive Independent Director of Cellectis SA since October 2011. From 2006 to 2012, Mr. Arthaud held the position of Deputy Chief Executive Officer at CDC Entreprises. From 2009 he also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004 he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the Ecole Polytechnique and the l’Ecole Nationale de Statistique et d’Administration Economique. He is currently on the Board of Directors of Adocia, TxCell, Calyxt Inc. and Aledia, among others.

Pierre Bastid

Mr. Pierre Bastid has served as Non-Executive Independent Director of Cellectis SA since October 2011. He has been Member of the Board of Directors of HOUGOU S.A. since 2011. He also currently serves on the Boards of Directors of HOUGOU Development S.A., Louise 342-344 S.A., Shango S.A., Hebioso S.A., Nepteam S.A.S. and Pharnext SAS. From 2005 to 2011, he served as the President and Chief Executive Officer of Converteam Group S.A.S. (formerly Alstom Power Conversion). From June 2011 to July 2014, he was also a Member of Board of Directors of Zaka S.A. From 2008 to 2011, Mr. Bastid served as President and a Member of the Board of Directors of CVT Holding S.A.S. and as President of Financiere CVT S.A.S. From 2009 to 2011, he served as President of CMC Kilimanjaro, CMC Everest, CMC Mac Kinley, CMC Elbrouz and CMC K2. He graduated from Ecole Centrale de Lyon and INSEAD.

Rainer Boehm

Mr. Rainer Boehm, M.D., has been Non-Executive Independent Director of Cellectis SA since June 26, 2017. Currently, he serves also on the Board of Directors at Rohner AG and Humanigen Inc. He graduated Universitaet Ulm with degree in Medicine as well as Schiller International University with master of business administration degree.

Alain Godard

Mr. Alain Godard has served as Non- Executive Independent Director of Cellectis SA since October 2007. He began his agronomy career in 1967 in Africa as a researcher at the l’Institut de Recherche pour les Huiles et Oleagineux (Institute for Research on Oils and Oleaginous Plants). Since 2002, Mr. Godard has been a consultant in plant biotechnology and management. He has been Manager of SARL Godard & Co, and he also serves on the Board of Directors of Cakyxt Inc. He previously served as Chairman of the Management Board of Aventis Cropscience from 1999 to 2001 and served on the Executive committee of Aventis Cropscience for the same period. He held several executive positions at Rhone-Poulenc Agrochimie since joining in 1975, and he became CEO of the company in 1991 and chairman and CEO in 1995. Mr. Godard was appointed to the executive Committee of the Rhone-Poulenc group in 1997, where he oversaw operations in the field of animal and plant health and the group’s Asia region. In 1999 he was an active player in the merger of Hoechst and Rhone-Poulenc, which resulted in the founding of Aventis. Mr. Godard is a graduate of the Ecole Nationale Superieure Agronomique de Toulouse.

Herve Hoppenot

Mr. Herve Hoppenot has been Non-Executive Independent Director of Cellectis SA since June 26, 2018. Currently, he serves also as Chairman of Incyte Inc.

Jean-Marie Messier

Mr. Jean-Marie Messier has been Non-Executive Independent Director at Cellectis SA since May 2015. He is co-founder of Messier Maris & Associes, a high-end international investment banking firm. After graduating from Ecole Polytechnique, Mr. Messier attended the Ecole Nationale d’Administration. He became in 1988 Managing Partner at Lazard Freres, position he held for six years. Prior to this, he was responsible for the French Government’s Privatization plan. As such, he privatized companies among which Alcatel, Lagardere, Saint Gobain, Suez and Societe Generale. Mr. Jean-Marie Messier served as President of Vivendi Universal (former Compagnie Generale des Eaux) from 1994 to 2002. During these years, he founded the mobile firm Cegetel and turned Vivendi into a conglomerate focused on two core activities: utilities (water, power and transport) and communications (pay TV, telecoms and internet), selling off assets in other areas. Mr. Jean-Marie Messier serves also as Director of Rentabiliweb Group.

Annick Schwebig

Dr. Annick Schwebig has served as Non-Executive Independent Director of Cellectis SA since October 2011. In 2000, she founded the French subsidiary of biopharmaceuticals company Actelion. Dr. Schwebig worked as a senior manager at the Bristol-Myers Squibb for 17 years from 1983 to 2000. She is a graduate of the University of Paris Medical School. Currently, she serves on the Board of Directors of Inventiva Pharma, Inserm-Transfert SA and B Cell Design.